Microbot Medical Expands Manufacturing with Sanmina as LIBERTY System Demand Surges
Event summary
- Microbot Medical signed a Letter of Agreement with Sanmina to manufacture the LIBERTY Endovascular Robotic System.
- The move aims to meet rising U.S. and international demand, including recent clearance in Israel and progress toward CE Mark.
- Sanmina’s global manufacturing network will diversify production, improve operating efficiencies, and expand gross margins.
- Microbot plans to increase its sales footprint to the Western U.S. later this year.
The big picture
Microbot Medical’s partnership with Sanmina reflects a strategic pivot to address surging demand for its LIBERTY System, aligning with broader trends in robotic-assisted endovascular procedures. The deal underscores the importance of scalable manufacturing in medical device commercialization, particularly as regulatory approvals expand beyond the U.S.
What we're watching
- Regulatory Momentum
- The pace at which Microbot secures additional international clearances, particularly the CE Mark.
- Execution Risk
- Whether Sanmina can scale production efficiently to meet near and long-term demand.
- Market Expansion
- How quickly Microbot penetrates the Western U.S. market after its planned sales expansion.
Related topics